Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on oncology and immunology. The Company is building its robust portfolio and differentiated pipeline through internal R&D capability, collaborations with co-discovery and co-development partners and select acquisitions. The Company’s proprietary antibody technology platforms Harbour Mice® generate fully human monoclonal antibodies in two heavy and two light chain (H2L2) format, as well as heavy chain only (HCAb) format. Building upon the HCAb antibodies, the HCAb-based immune cell engagers (HBICE®) are capable of delivering tumor killing effects unachievable by traditional combination therapies. Integrating Harbour Mice® with single B cell cloning platform, our antibody discovery engine is highly unique and efficient for development of next generation therapeutic antibodies. For more information, please visit www.harbourbiomed.com

Website: http://www.harbourbiomed.com

Employees: 103

HQ: +86 21 5339 9123

Location: Cambridge, Massachusetts, US

Revenue: $23 million

Are you looking for contact information for Harbour Biomed? Look no further than ConnectPlex.ai! Our extensive database contains company information for millions of businesses around the world, including Harbour Biomed. With our easy-to-use platform, you can quickly and easily find the contact details you need to connect with the right people and grow your business. At ConnectPlex.ai, we understand the importance of accurate and up-to-date information. That's why we're committed to providing the most current and reliable data available. Our team works tirelessly to ensure that our database is constantly updated and expanded, so you can be sure that you're getting the most comprehensive and relevant information possible. Whether you're looking to connect with key decision-makers, expand your network, or explore new business opportunities, ConnectPlex.ai is the perfect resource to help you achieve your goals.

Harbour BioMed: Revolutionizing the Future of Biopharmaceuticals In the heart of Cambridge, Massachusetts, a vibrant hub of innovation and technology, lies Harbour BioMed, a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics. With a focus on oncology and immunology, Harbour BioMed is pioneering the use of transgenic mouse technology to generate fully human monoclonal antibodies, heavy chain only antibodies, and HCAb-based immune cell engagers. The company's proprietary antibody technology platforms, Harbour Mice®, are capable of producing fully human monoclonal antibodies in two heavy and two light chain (H2L2) format, as well as heavy chain only (HCAb) format. These HCAb antibodies can be used to deliver tumor-killing effects that traditional combination therapies cannot achieve. By integrating Harbour Mice® with a single B cell cloning platform, Harbour BioMed's antibody discovery engine is highly unique and efficient, allowing for the development of next-generation therapeutic antibodies. With a robust portfolio and differentiated pipeline, Harbour BioMed is building a strong presence in the BioTech/Drugs industry. Founded in 2014, the company has quickly grown to 100-249 employees and boasts a revenue of 2.5-5 million. Their commitment to innovation and progress has earned them recognition and support from leading investors and partners in the industry. Harbour BioMed's management team, led by CEO April Huang and CFO Yingying Chen, is dedicated to advancing the company's mission to revolutionize the future of biopharmaceuticals. With a strong focus on research and development, Harbour BioMed is poised to make a significant impact in the fight against cancer and other diseases. For more information, visit Harbour BioMed's website at harbourbiomed.com or follow them on LinkedIn at http://www.linkedin.com/company/harbour-biomed.

Harbour BioMed is a global company that creates new medicines to help people fight cancer and immune system diseases. They have a strong team of scientists who work together to discover, develop, and sell these medicines. They use special technology to create these medicines, like Harbour Mice®, which are mice that have been changed to make human antibodies. They also have a way to make sure the medicines are really effective, called HCAb-based immune cell engagers (HBICE®). This technology helps the medicines kill cancer cells in a way that other treatments can't. They also use a special way to find the best antibodies, called single B cell cloning, which makes their discovery process very efficient. You can learn more about Harbour BioMed and their work by visiting their website, www.harbourbiomed.com.